Cargando…
MicroRNA-153-3p sensitizes melanoma cells to dacarbazine by suppressing ATG5-mediated autophagy and apoptosis
BACKGROUND: Dacarbazine is one of the most commonly used chemotherapeutic agents for the treatment of melanoma; however, only 5–10% of patients benefit from this treatment. MicroRNA-153-3p (miR-153-3p) has a tumor-suppressive effect in melanoma. In the present study, we found that miR-153-3p was dow...
Autores principales: | Hou, Shaowei, Guo, Minfang, Xi, Haiying, Zhang, Lianqing, Zhao, Ailing, Hou, Heng, Fang, Wuning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798736/ https://www.ncbi.nlm.nih.gov/pubmed/35117926 http://dx.doi.org/10.21037/tcr-20-2660 |
Ejemplares similares
-
Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016) -
Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014) -
miR 204-5p inhibits apoptosis in dacarbazine-treated melanoma cells
por: PALKINA, NADEZHDA, et al.
Publicado: (2022) -
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000) -
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)